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The Dialysis Outcomes and Practice Patterns Study (DOPPS): complications, such as vascular access failure, at consid-
An international hemodialysis study. The Dialysis Outcomes erable expense and morbidity. The Dialysis Outcomes
and Practice Patterns Study (DOPPS) is a prospective, longitu- and Practice Patterns Study (DOPPS) is a prospective,dinal, observational study of hemodialysis patients and facilities
international, observational study of hemodialysis prac-in seven countries with large populations of dialysis patients:
tices and associated outcomes. The primary goal ofFrance, Germany, Italy, Japan, Spain, the United Kingdom,
and the United States. This paper describes the study design, DOPPS is to improve the understanding of dialysis prac-
analytic methods, and preliminary findings of the DOPPS. The tices that are associated with better outcomes for pa-
goal of the study is to determine which practice patterns are tients. The primary study endpoints are mortality, hospi-associated with the best patient outcomes, with adjustment for
talization, quality of life, and vascular access outcomes.a wide range of patient case-mix characteristics. The primary
DOPPS is predicated on several observations. First,outcomes of interest are mortality, hospitalization, quality of
life, and vascular access events. The facility sample from the although the overall mortality rate is exceedingly high
seven countries consists of 327 hemodialysis centers in which among dialysis patients, outcomes vary substantially
24,392 patients were treated when the study began. A random
across facilities and countries [1–4]. For example, a five-sample of 10,332 patients has been selected thus far for more
fold variation in crude mortality was reported acrossdetailed longitudinal data collection. Departing patients are
replaced during the study using random selection. A study facilities in the United States and adjusted mortality indi-
coordinator at each dialysis facility collects baseline and longi- cators show comparable variability [1, 2]. Also, the re-
tudinal patient data. Patients are asked to complete a question- ported 5-year mortality rates for end-stage renal disease
naire that addresses quality of life on a yearly basis. The medical
(ESRD) patients in Europe and Japan are 20–35% lowerdirector and nurse manager in each facility complete a practice
than those reported for patients in the United States,pattern questionnaire. Preliminary data are presented concern-
ing the sample facilities and the census of patients treated in even with adjustment for age, sex, and diabetic status
each facility at the start of the study. Dialysis facilities vary [3]. The observed variation in mortality across centers
widely in size and type (freestanding vs. institutionally-based) and countries raises the strong possibility that differing
across countries. Variation is also seen in patient age, sex distri-
treatment practices may contribute to the variation inbution, and diabetes mellitus as the attributed cause of end-
outcomes. Second, dialysis outcomes can be modified bystage renal disease (ESRD). At this early phase, the DOPPS
has proved to be technically feasible and has revealed basic changes in dialysis practice. For example, several studies
differences in hemodialysis facilities and patients across the have shown that improved patient survival is associated
seven participating countries. with higher dialysis doses and use of different types
of dialysis membranes [4–6]. Finally, observational stud-
ies have proven to be an efficient means for discover-
Dialysis therapy ameliorates many of the clinical mani- ing associations between treatment patterns and out-
festations of renal failure and postpones otherwise immi- comes [4, 5, 7–9]. Findings from large, well-designed,
nent death. Despite this undeniable success, hemodialy- nationally representative observational studies have
sis patients have higher mortality and hospitalization prompted changes in the national practice of dialysis and
rates and lower quality of life than the general popula- provided the impetus for important clinical trials [10, 11].
tion. Also, patients must contend with unique treatment DOPPS was designed to address some of the limita-
tions of international registries, which often rely on vol-
untary reporting and collect little information aboutKey words: end-stage renal disease, mortality, hospitalization, quality
of life, vascular access outcomes. practice patterns and individual patient characteristics.
DOPPS also addresses the limitations of studies involv- 2000 by the International Society of Nephrology
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ing single facilities or convenience samples of facilities mean age and percentage of diabetic patients in each
facility [12]. The AMR estimates the standardized mor-by studying a representative sample of dialysis centers
and patients. DOPPS was designed to study inter-facility tality ratio (SMR), which is the ratio of observed to
expected deaths in a facility where expected deaths arevariation in hemodialysis practices and outcomes in the
hopes of identifying important, potentially causal associ- based on the age, race, sex, and diabetic status of each
patient treated in the center [13]. The AMR is based onations. Variation in practice patterns was achieved
through a sample design that included dialysis facilities average rather than individual patient characteristics. A
simple random sample of 97 dialysis facilities was initiallyfrom seven developed countries with large ESRD popu-
lations: France, Germany, Italy, Japan, Spain, the United selected without regard to the AMR. In order to augment
the representation of facilities with extremes in outcomesKingdom, and the United States. The study features lon-
gitudinal collection of dialysis facility practices, patient (and potentially in practice patterns), a purposive sample
of 31 facilities was drawn from the upper tail and 33 fromoutcomes, and patient demographics, comorbidities, and
laboratory values. The study is unique in the breadth the lower tail of the AMR distribution. A representative
description of U.S. dialysis facilities can be obtained us-and detail of the information collected regarding demo-
graphic characteristics, comorbid conditions, clinical out- ing the random sample or the overall sample weighted
by the probability of facility selection.comes, and treatment practices for each patient and cen-
ter. Our intent is to clarify risk factors for deleterious In Europe, the sample is composed of 20 dialysis cen-
ters from each of the five participating countries for apatient outcomes while accounting for the confounding
effects of patient case-mix. This report describes the total of 100 facilities. Facilities were sampled from all
dialysis facilities in each country, obtained from nationalstudy design and delineates the baseline characteristics
of the dialysis facilities and patients. sources with the assistance of the country investigators.
Within each country, the sample was proportionately
stratified by geographic region and facility type in order
METHODS
to assure that the facilities were representative (Table 1).
Study design As the number of geographic regions generally exceeded
the sample size, sample stratification was achieved byDOPPS is a prospective study of hemodialysis patients
and facilities in seven countries. The countries were se- setting a maximum quota for each region. The facility
type strata were determined by the conventions used inlected on the basis of geographic diversity, variation in
practices and outcomes, and relatively large numbers of each country (e.g., center vs. satellite centers, described
in Table 1). In Japan, 66 dialysis facilities were enrolledESRD patients. A nationally representative sample of
dialysis facilities has been enrolled in each country. A from a national list of hemodialysis facilities. The sample
was stratified by geographic region (prefecture) and facil-random sample of hemodialysis patients is selected
within each participating center. Practice patterns are ity type (Table 1).
Facilities treating fewer than 20 chronic hemodialysisdetermined at the facility and patient levels. Demo-
graphic, laboratory, comorbidity, and outcome data are patients in the US and fewer than 25 elsewhere were
excluded for reasons of study efficiency (the minimumascertained at the patient level. The basic study design
and study instruments are shared across all countries size was increased for Europe and Japan because fewer
facilities were enrolled than in the United States). Thiswith minor local modifications as necessary.
Institutional review boards approved the study in each restriction led to the exclusion of fewer than 5% of all
hemodialysis patients in each country. Facilities treatingcountry or facility, as required. Informed patient consent
was obtained in accordance with the requirements of less than the threshold number of patients after recruit-
ment (because the patient count declined after facilityeach country, review board, and dialysis center. Data
collection is performed in a fashion that maintains pa- enrollment) were retained in the study.
tient anonymity at the coordinating center.
Patient sampling
Facility sampling At the start of the project, the study coordinator in
each participating facility listed the census of prevalentIn the United States, a stratified random sample of
chronic hemodialysis facilities was selected to achieve in-center hemodialysis patients older than 17 years. This
census listing includes basic patient information such asvariation in practice patterns and outcomes. The initial
sampling frame consisted of a random subsample of a age, race, sex, and the cause of ESRD. At regular inter-
vals of approximately every four months, the census islisting of dialysis facilities published by the Health Care
Financing Administration (HCFA). For each dialysis fa- updated to indicate all new and departed patients since
the last census update. The date and reason for eachcility, a measure of mortality was estimated using the
adjusted mortality ratio (AMR) for the year 1996, based departure are entered on the census form. Within each
participating facility, the census listing was used to selecton publicly available measures of crude mortality and
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Table 1. Summary of hemodialysis facilities in sampling frame for each country, 1996–1999
No. of No. of
Total Total HD geographic facility
Country facilities patients regionsa typesb Facility typesb
France 316 20,106 22 4 General, private, university, association
Germany 790 43,747c 10 3 Clinics (medical centers), nonprofit
free-standing, private practice
Italy 599 30,963c 19 2 Public, private
Japan 2653 158,222d 47 2 Hospital, clinic
Spain 476 15,427c 83 2 Academic, non-academic
United Kingdom 146 7,528d 11 2 Center, satellite
United States 2894 159,349e 1 3 Free-standing profit, free-standing
non-profit, hospital
HD 5 hemodialysis, No. 5 number
a Number of regions in each country sample frame used in sampling plan. U.S. sample was not stratified by geographic region.
b Number of facility types used in sampling plan. U.S. sample was not stratified by facility type although facility strata in common use are shown for comparison
with other countries.
c Data obtained directly from European Dialysis and Transplant Association (EDTA) for 1995
d Data from Japanese Society for Dialysis Therapy for 1997 [17]
e Data from United States Renal Data System (USRDS) for 1995 [16]
a random sample of 20–40 patients, varying according director and the nurse manager (or designee) at each
dialysis center. These surveys address a wide range ofto the size of the facility. Detailed longitudinal data col-
lection is performed for this representative sample of practice and management issues including dialysis pre-
scription, water quality, dialyzer re-use practices, staffingpatients. Departed patients are replaced approximately
every four months, using random selection from the pa- patterns, nutrition, vascular access, and health mainte-
nance (Table 3) and are repeated at yearly intervals. Intients entering the dialysis facility during the interval.
addition, the summary of patient-specific treatments at
Data collection the facility level provides valuable information about
practice patterns.A study coordinator in each participating dialysis cen-
ter performs data collection. In addition, specific ques- The same data collection instruments are used in each
country, with minor modifications as appropriate (i.e.,tionnaires are completed by sampled patients, the medi-
cal director, and the nurse manager of each participating incorporation of local terminology, deletion of answer
choices known to be unavailable). The questionnairesfacility. The cumulative census form provides basic data
about all hemodialysis patients treated in each facility were translated from American English to French, Ger-
man, Italian, Japanese, Spanish, and Queen’s English.(see above). The study coordinator completes a detailed
medical questionnaire for each patient selected for the In each country, the translated questionnaires were re-
viewed for meaning and context by nephrologists andsample. Medical questionnaire information is largely ab-
stracted from the medical record, supplemented by per- pretested in dialysis centers not selected for the study.
sonal knowledge of the patients. The medical question-
Sample sizenaire addresses a variety of areas including ESRD
history, medical and psychosocial history, dialysis pre- The primary goal of the study is to find associations
between the observed variation in practice patterns andscription, laboratory data, and prescribed medications
at the time of study enrollment (Table 2). The study patient-level outcomes, while accounting for patient
case-mix and facility clustering effects. A secondary goalcoordinator completes an interval summary approxi-
mately every four months for each sampled patient. The is to describe dialysis patients and practices within each
country. The study was designed to investigate associa-interval summary updates laboratory data, dialysis pre-
scription, medication use and the interval occurrence of tions between multiple practice patterns and four specific
outcomes (mortality, hospitalization, quality of life, andhospitalizations, outpatient events and medical interven-
tions, vascular access events, and departures (Table 2). vascular access events). However, for design purposes,
the size of the facility and patient samples was plannedPatients are asked to complete a questionnaire that in-
cludes the Kidney Disease Quality of Life survey based on finding differences in mortality. In Europe,
with the smallest sample size per country, the study has(KDQOLe) [14] and modules concerning pre-ESRD
care, economic aspects of ESRD, employment and reha- a designed power of 90% to detect a mortality difference
of 4% between two equal size aggregated groups of dial-bilitation. Patients repeat the KDQOLe survey each
year. ysis units with different practice patterns of interest. The
facility and patient sample from the entire worldwideFacility practice patterns are measured by comprehen-
sive questionnaires that are completed by the medical study will achieve higher power to detect smaller mortal-
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Table 2. Patient level data collection items
Category Illustrative data items MQa ISb
Background and demo-
graphic information Age, sex, race, ESRD history X —
Insurance coverage Primary and secondary payer X X
Medical history Cause(s) of ESRD, tobacco use, heart disease, cerebrovascular disease, periph-
eral vascular disease, diabetes mellitus, pulmonary disease,
neurologic disease, psychiatric disease, musculoskeletal disease,
gastrointestinal and hepatic diseases, cancer, eye disease, hepatitis,
HIV, family history X —
Pre-ESRD treatment Nephrologist visit, vascular access X —
Vital signs Blood pressure, weight X X
Dialysis prescription Time, dialyzer, dialysate composition, blood flow X X
Psychosocial evaluation Employment history, education, social support X —
Laboratory data Electrolytes, BUN, creatinine, albumin, hemoglobin, hematocrit, iron, PTH,
lipids X X
Residual renal function Timed urine collection for urea/creatinine X X
Medications List of medications X X
Vascular access history Type and location of current access, number of prior temporary and permanent
accesses X —
Vascular access events Type, location at start and end of interval; all changes in access status; procedures,
creation/placement — X
Hospitalizations Dates, diagnosis, and procedures for each interval hospitalization — X
Outpatient events Dates, diagnosis, and procedures for each outpatient encounter — X
Interval status Dialysis status at end of reporting interval, date and cause of departures — X
Quality of life Kidney Disease Quality of Life Instrument (KDQOL) (patient questionnaire) —
a Medical Questionnaire (MQ) provides baseline information at time of patient enrollment in DOPPS
b Interval Summary (IS) provides follow-up information for each 4-month study interval
Table 3. Facility level data collection items
Anemia and iron therapy Facility characteristics Mineral metabolism
Antihypertensive therapy Facility staffing practices Nurse and technician practices
Continuing education policies/practice Health care maintenance Patient turnover
Dialysate processing and composition Hospital and outpatient practices Physician practices
Dialysis dose Immunizations Pre-ESRD practices
Dialysis machines Information systems Quality assurance and
improvement practices
Dialysis practices Initiation and discontinuation of dialysis Scheduling practices
Dialyzer re-use Insurance policies Social service practices
Dialyzers Laboratory testing Vascular access
Dietitian and nutrition practices Local dialysis market Water treatment and surveillance
ity differences. In general, the power to detect clinically (such as census-based mortality rates) and outcomes
among only the sampled patients.important differences in the other major outcomes by
In this report, selected facility and patient characteris-differences in treatment practices should be greater than
tics are expressed using standard descriptive statistics.for the dichotomous and rarer outcome of death.
Statistical comparisons across countries were performed
Data management and analysis using linear regression for continuous variables and lo-
gistic regression for categorical variables. Patient dataA database is maintained at the central coordination
for the United States were drawn from the randomlyand analysis center. A series of range and logical data
selected group of facilities. The United States was arbi-checks are performed programmatically. Multivariate re-
trarily selected as the reference group as it contains thegression techniques are planned for analyses of the major
largest number of study facilities and patients. A P-valueoutcome variables. Explanatory covariates will include
less than 0.05 is considered statistically significant.both patient variables such as age, sex, race, and comor-
bid factors, and facility variables such as practice pat-
RESULTSterns. Facility level factors will be evaluated using tech-
niques that account for facility clustering. Analyses will The study was initiated sequentially in the United
States, then Europe, and finally Japan, between 1996be conducted to consider both facility-level outcomes
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Fig. 1. Geographic distribution of DOPPS dialysis units in the United States (A), Europe (B), and Japan (C). One extra facility has been placed
on each country map to preserve anonymity of facilities. In panel A, three facilities in Alaska and Hawaii are not shown.
and 1999 and is currently (September 1999) ongoing in Table 4 displays basic characteristics of the DOPPS
dialysis facilities by country. Large variation in facilityall countries. The DOPPS sample is intended to repre-
sent the patients (approximately 435,000) and hemodial- size (number of patients treated) was found in all coun-
tries, as indicated by the range between the minimumysis facilities (approximately 8000) in the seven partici-
pating countries (Table 1). The DOPPS facility sample and maximum size. Although facilities treating a small
number of patients were not eligible, at least one centercurrently consists of 327 hemodialysis centers. These cen-
ters had a total census of 24,392 patients at the start of fell below the threshold by the time of the initial census.
On average, facilities are largest in Japan and the Unitedthe study. Thus far, a sample of 10,332 patients have
entered detailed longitudinal study (including departed States and smallest in Spain. Institutionally based facili-
ties (e.g., hospital, university, academic, public) predomi-and replacement patients). The overall facility accep-
tance rate was 77.4%. Figure 1 shows the geographic nate in all countries except Germany, the United States,
and Japan where free-standing facilities are more com-distribution of the participating dialysis facilities.
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Table 4. Characteristics of enrolled DOPPS dialysis facilities by country, 1996–1999
Number of hemodialysis patients Type of facility
Enrolled
Country facilities Mean Median Mina Max Freestanding (%)b Institutional (%)c
France 20 64 59 32 111 40 60
Germany 20 60 55 30 110 80 20
Italy 20 65 54 25 219 40 60
Japan 66 96 71 26 426 56 44
Spain 20 53 50 25 90 50 50
United Kingdom 20 62 58 26 160 50 50
United States 161 81 70 15 369 71 29
a Small units excluded from study
b Freestanding includes clinics, private and other non-institutionally based facilities
c Institutional includes hospital-based, university, academic, and public facilities
Table 5. Comparison of DOPPS patient characteristics by country
Age (years) Male (%) Diabetes mellitus as cause of ESRD (%)
Country Meana P-valueb % ptsa AORc P-valuec % ptsa AORd P-valued
France 60.4 0.3569 57.8 1.18 0.0087 10.4 0.16 0.0001
Germany 60.1 0.8847 54.3 1.04 0.5292 25.0 0.48 0.0001
Italy 62.2 0.0001 55.1 1.07 0.2496 10.7 0.17 0.0001
Japan 58.8 0.0001 61.1 1.36 0.0001 23.9 0.46 0.0001
Spain 60.9 0.0541 56.8 1.15 0.0362 19.5 0.34 0.0001
United Kingdom 58.1 0.0001 62.0 1.39 0.0001 14.6 0.25 0.0001
United States 60.0 ref 52.9 ref ref 40.9 ref ref
AOR 5 adjusted odds ratio; pts 5 patients; ref 5 reference group.
a Unadjusted
b Adjusted for sex and diabetes
c Adjusted for age and diabetes
d Adjusted for age and sex
mon. Dialysis facility size and type are examples of char- and less than 1% in all other countries. Blacks consti-
tuted 39.5% of patients in the U.S. and less than 3% inacteristics (practice patterns) that could plausibly influ-
ence patient outcomes. Europe. In general, racial variation was much higher in
the U.S. than in the other countries.Table 5 shows basic characteristics of prevalent hemo-
dialysis patients by country. Patient age varies signifi-
cantly across countries. The average patient age is lowest
DISCUSSIONin the United Kingdom and Japan and highest in Italy
ESRD practice patterns and outcomes, particularlyand Spain. The majority of hemodialysis patients in all
mortality, have been reported to vary across countriescountries are men. However, the percentage of male
and treatment facilities [1–3]. These variations presenthemodialysis patients is lower in the United States than
an important opportunity to associate the practice pat-all other countries, significantly so for France, Japan,
terns and patient factors that influence patient outcomes.Spain, and the United Kingdom. For example, the odds
DOPPS will exploit the variation in treatment practicesof a patient being male are 36% higher in Japan than
and outcomes, adjusting for variation in patient case-the United States and 39% higher in the United King-
mix, to assess the relationships between unit practicesdom than the United States, adjusted for differences in
and outcomes, with special emphasis on mortality, hospi-age and diabetes mellitus as the cause of ESRD. Diabetes
talization, vascular access, and quality of life. DOPPSmellitus as the attributed cause of ESRD was much
differs from many prior studies in taking careful stepshigher in the United States than in the other countries.
to represent the target populations adequately and in theMoreover, the prevalence of diabetic ESRD varied dra-
detailed collection of practice pattern and longitudinalmatically even within Europe, ranging from 10% in
patient data. DOPPS is principally based on variationFrance to 25% in Germany.
across dialysis facilities, not countries. Indeed, it is notExpected differences in patient race were reported
a major goal to compare outcomes among countries.across countries. In the United States 52% of hemodialy-
However, the study was stimulated in part by differencessis patients were Caucasian as compared with 84–99%
in mortality as reported by ESRD registries so it is inter-in the five European countries. Virtually 100% of pa-
esting to compare basic characteristics of dialysis facili-tients in Japan were listed as Asian race compared to
3.7% in the United States, 2.3% in the United Kingdom, ties and patients. Rigorous analysis of practice patterns
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and outcomes requires careful adjustment for patient males differed by almost 10% across countries. Kidney
disease and ESRD are more common among men thancharacteristics [8]. DOPPS is designed to characterize
the demographic, comorbid, and practice characteristics women. However, the sex distribution varies by cause
of ESRD. Thus, country differences in patient sex ratioof the participating patients to a greater degree than any
previous large observational dialysis study. may reflect differences in the causes of kidney disease.
Diabetic ESRD is more common in women than men.At this early phase of the study, DOPPS has already
illustrated the feasibility of enrolling representative sam- Although diabetes is more frequent as the attributed
cause of ESRD in the United States than elsewhere, theples of dialysis facilities from seven nations with large
variation in sex distribution persists after adjustment forESRD populations. This is the first major prospective
diabetes and age (Table 5).study of dialysis outcome across three continents. The
The observed variation in diabetes mellitus as the at-prospective design of DOPPS and its careful tracking of
tributed cause of ESRD across countries (Table 5) isall outcomes should provide more accurate data than
not explained by country differences in the age or sexprior, retrospective studies of dialysis registry data. Rep-
distribution. By far, the highest prevalence of diabeticresentative enrollment of facilities exposes variation and
ESRD is found in the United States. However, the preva-facilitates description of measured characteristics within
lence also varies by more than a factor of two withineach participating country. In contrast, most prior studies
the European countries. Multiple potential explanationsdescribed experience in a single center or a convenient
exist including variation in the underlying prevalence ofgroup of centers and thus sacrificed the ability to general-
diabetes, diagnostic criteria, pre-ESRD treatment, andize the findings. It is difficult to conduct a study using a
referral and acceptance patterns. Diabetes mellitus is arepresentative sample of dialysis facilities because many
quantitatively important predictor of ESRD outcomesof the randomly selected facilities are unaccustomed to
and must be considered when evaluating associationsparticipation in research endeavors. Nonetheless, we
between practice patterns and outcomes.have experienced high enthusiasm among participating
As expected, the reported race of ESRD patients var-centers and excellent compliance to the study plan. The
ies across countries, as does the racial composition ofoverall acceptance rate of 77.4% is encouraging and
the national populations. The racial composition of he-strong efforts will be made to retain facilities for up to
modialysis patients is relatively homogeneous in Europefive years of longitudinal data collection in the United
and Japan as compared with the United States. TheStates and two years elsewhere. In addition, information
race classifications used at the DOPPS facilities generallywill be sought on facilities that declined to participate
indicate the judgments of patients or dialysis staff mem-in order to identify possible non-response bias.
bers. Race classification raises important scientific andThe DOPPS facility sample shows variation in the
social questions [15]. Nonetheless, race classification hasnumber of patients treated at the different centers (Table
proven useful for exploring psychosocial, economic, and4). The average and range of treated patients per facility
genetic aspects of ESRD in the United States [16]. Racewas larger in Japan and the United States than for Euro-
will be considered as a possible confounding factor inpean countries. Furthermore, patients are less likely to
the association between practice patterns and outcomes.be treated at institutionally based facilities in Germany,
This report clearly demonstrates the feasibility of thethe United States and Japan compared with the other
worldwide DOPPS study and describes the internationalcountries. These attributes should be viewed as putative
variation in several characteristics of hemodialysis treat-practice patterns that may be associated with patient
ment facilities and patients. We expect to observe associ-outcomes.
ations between practice patterns and outcomes, adjustedPatient characteristics such as age, sex, race, and dia-
for important patient characteristics, which should leadbetic status were also found to vary across countries
to improvements in clinical care and help direct future(Table 5). These basic patient characteristics likely re-
clinical trials.flect multiple, complex, interacting factors including dif-
ferences in the burden of kidney disease, ESRD accep-
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